Opinion|Videos|May 5, 2025
Comprehensive Molecular Testing in Patients With Ovarian Cancer
Author(s)Bradley J. Monk, MD, FACS, FACOG
A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for better education of health care providers and more affordable, widely available testing options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Challenges in Comprehensive Molecular Testing
Two primary barriers impact comprehensive molecular testing implementation:
Education:
- Physicians need better awareness about which tests to order, when to order them, and how to interpret results.
- All patients with advanced or recurrent disease should receive comprehensive testing (DNA, RNA, and protein analysis).
- Education must extend to health care providers, patients, and the broader community.
Cost and reimbursement:
- Medicare covers several biomarker tests with little to no patient cost.
- Reimbursement varies by insurance type, with inconsistencies in federal and state funding.
- Improving value requires both better education and more affordable testing options.
Addressing these barriers would support wider adoption of comprehensive molecular testing in ovarian cancer.
Advertisement
Related to this article
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.
Advertisement
Advertisement
Trending on AJMC
1
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
2
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
5